The COVID-19 Global Health Crisis
One Year Later
The East Asia Center (EAC) and South Asia Center (SAC) are pleased to support the Spring Quarter 2021 Global Business Forum taught by Professor Christina Fong, in partnership with the Foster School’s Global Business Center, the School of Law’s Global Business Law Institute, and the National Bureau of Asian Research (NBR).
The Global Business Forum (GBF) is an engaging MBA class and discussion forum where professionals from around the world share their insights into the complexities of doing business globally. The GBF is designed to connect students directly with global business leaders, and this is accomplished in part by inviting such leaders for panel discussions around a specific topic chosen for each quarter the course is offered.
The Spring 2021 GBF course topic is, “The COVID-19 Global Heath Crisis: One Year Later.”
Distinguished guests will join the course to describe how their companies and industries have changed since the spring of last year. In particular, they will address questions such as: Will the global travel industry have recovered? What new technologies/companies have arisen to address the challenges presented by the crisis? Which global economies rebounded the most quickly and why?
The EAC and SAC are especially pleased to partner with NBR to bring Linda Distlerath, Senior Advisor of NBR and Board Member of the National Academy of Certified Care Workers, to this quarter’s GBF. The full list of guests are as follows:
**Sessions are open to JSIS Graduate Students – contact [email protected] for access. These class sessions will not be recorded and are not open to the public.**
May 3: Global Supply Chains Panel
Alexis DePree, Chief Supply Chain Officer, Nordstrom
Jeff Dickerman, Senior Vice President, General Counsel & Corporate Secretary, Expeditors
May 17: Global Pharmaceuticals Panel
Linda Distlerath, Senior Advisor, The National Bureau of Asian Research and Director, National Academy of Certified Care Managers
Edward Nowicki, Senior Vice President, Corporate Compliance, Pfizer